What are the recent financial highlights of ONESOURCE SPECL PHARMA L?

ONESOURCE SPECL PHARMA L recently reported a total revenue of ₹1,092.04 Cr and a net profit margin of -14.34%. These metrics reflect the company’s consistent financial performance.

What are the key financial metrics of ONESOURCE SPECL PHARMA L?

Key financial metrics include a trailing P/E ratio of , forward P/E of , book value of ₹1216.066, price-to-book ratio of 1.0863309, and a market capitalization of ₹151.18 billion.

What does ONESOURCE SPECL PHARMA L do?

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India and internationally. The company provides end-to-end CDMO services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. OneSource Specialty Pharma Limited was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. The company was incorporated in 2007 and is based in Bengaluru, India.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Onesource

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Onesource

Latest updates related to Onesource

Sr No.	Title	Sentiment
1	360 ONE Asset acquires stake in OneSource Specialty Pharma The Economic Times	🔄
2	3 firms divest 6.8% stake in Onesource Specialty Pharma for Rs 1,202 crore Business Standard	🔄
3	OneSource Specialty Pharma strengthens Board by appointing three new Independent Directors BSI bureau	🔄
4	OneSource Specialty Pharma aims for $400 million revenue in 3-4 years CNBCTV18	🔄
5	Strides Pharma share price jumps over 9% on announcing OneSource share listing date Mint	🔄
6	Thomson Reuters unveils CoCounsel integration in ONESOURCE corporate tax solutions Thomson Reuters	🔄
7	OneSource Specialty Pharma Strengthens Board With Three Independent Directors BW Healthcare World	🔄
8	DSK Legal acts on listing of OneSource equity shares Bar & Bench - Indian Legal News	🔄
9	OneSource Specialty Pharma appoints three new independent directors Express Pharma	🔄
10	OneSource Specialty Pharma Achieves New High Amidst Broader Market Stability MarketsMojo	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Loading...

Loading...

Stock News - Onesource

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Credit ratings

Concalls

Explore More Stocks